HPVC2019-058 Pharmaceutical Products and IV Fluids

Current Contract

Contract Start Date
30 Jan 2020
Contract End Date
29 Jan 2022
Option Periods
2 x 2 Year

Description

Contract for the provision of a range of pharmaceutical products and intravenous fluids to Victorian Public Health Services.

Additional Information

Update 1: 29 March 2021

HPVITS2019-058.010 – Pharmaceutical Products and IV Fluids Supplementary 010

HSV is pleased to advise that the award outcome of the Supplementary tender 010 for subcategories 81001.02 RITUXIMAB 100 MG/10 ML INJECTION, AMPOULE/VIAL 10 ML and 81001.03 RITUXIMAB 500 MG/50 ML INJECTION, AMPOULE/VIAL 50 ML has been finalised and announced to health services on 24 March 2021.

  • Health service staff can now access to the updated HPVC2019-058 Pricing Schedule via secure login on the HealthShare Victoria website.

  • The award matrix will be made publicly available on the contract commencement date.

  • Contract commencement date is 1 April 2021.



Update 2: 12 March 2021

HPVITS2019-058.003 – Pharmaceutical Products and IV Fluids Supplementary 003
Please note that this tender is now accessible via the HSV Procurement Portal


Market Engagement Date: 1 March 2021 – 7 April 2021

Announcement of outcome to suppliers: 21 May 2021*

Announcement of outcome to health services: 4 June 2021*

Contract Commencement Date: 18 June 2021*

*Please note all dates listed are indicative dates 

Scope: 

Subcategory number Subcategory name

517.01

Arsenic trioxide 10mg/10mL injection, ampoule/vial,10mL

83001.01

Bevacizumab 100mg/4mL injection, ampoule/vial, 4mL

83001.02

Bevacizumab 400mg/16mL injection, ampoule/vial, 16mL

518.01

Bortezomib injection, ampoule/vial

519.01

Cabazitaxel 60mg injection, ampoule/vial

527.01

Carmustine 100mg injection, ampoule/vial

520.01

Daptomycin 350mg injection, ampoule/vial

520.02

Daptomycin 500mg injection, ampoule/vial

521.01

Deferasirox 90mg tablet/capsule 30

521.02

Deferasirox 180mg tablet/capsule 30

521.03

Deferasirox 360mg tablet/capsule 30

522.01

Desflurane 1mL/1mL or 1g/1g Inhalation solution, bottle 250mL

197.03

Furosemide (Frusemide) 20mg/2mL injection, ampoule/vial, 2mL

523.01

Imatinib 100mg tablet/capsule 30 (GIST indication)

523.02

Imatinib 100mg tablet/capsule 30 (non-GIST indication)

523.03

Imatinib 400mg tablet/capsule 60 (GIST indication)

523.04

Imatinib 400mg tablet/capsule 60 (non-GIST indication)

524.01

Methylprednisolone (sodium succinate) 500mg injection, ampoule/vial

524.02

Methylprednisolone (sodium succinate) 1g injection, ampoule/vial

325.02

Moxifloxacin 400mg tablet/capsule 5

525.01

Oseltamivir 30mg capsule 10

525.02

Oseltamivir 45mg capsule 10

525.03

Oseltamivir 75mg capsule 10

526.01

Sodium nitroprusside 50mg/2mL injection, ampoule/vial, 2mL

499.04

Vancomycin 500mg injection, ampoule/vial

Since this tender has been released, please direct all correspondence through the HSV Procurement Portal. For any difficulties accessing the HSV Procurement Portal, please contact helpdesk@healthsharevic.org.au for assistance.

 

Useful information:

1. To subscribe and receive contract update notifications, favourite this contract cabinet.
2. Review your account settings to ensure the notification frequency selected is adequate.
3. Information for Prospective Suppliers can be found on our website: https://www.hpv.org.au/tenders-and-contracts/information-for-prospective-suppliers/






Categories

Category 1 - Pharmaceutical Products
Category 50,000 - Intravenous Fluids
Category 60,000 - Parenteral Nutrition Solutions
Category 70,000 - Irrigating Solutions
Category 80,000 - Biopharmaceuticals
Category 90,000 – Therapeutic Group Approach